초록접수 현황
| 14F-215 | 구연 발표 |
Significance of New Parameter of PET/CT in Thymic Epithelial Tumors
김경수1, 오주현2, 문영규1, 박형주1, 성숙환1, 박재길1
가톨릭대학교 의과대학 서울성모병원 흉부외과학교실1, 서울성모병원 방사선과학교실2
Background : Thymic epithelial tumors have malignant potential that FDG PET/CT is used for treatment plan. SULpeak is the mean SUV corrected for lean body mass in a 1cc spherical volume of interest which is less affected by noise. We wanted to know the SULpeak including SUVmax have prognostic role in thymic epithelial tumors in comparison to the pathologic classification.
Methods : Between 2007 and 2014, the data of 32 patients (15 males, 17 females) diagnosed with thymic epithelial tumors who underwent PET/CT scan were retrospectively analyzed. Patients were divided into subgroups according to the histologic types: low-risk thymoma (type A, AB, B1) and high-risk thymoma (type B2, B3, C). We measured SULpeak and SUVmax to obtain the optimal cut-off values using ROC analysis. The high and low FDG uptake groups were divided according to the computed optimal cut-off values. The relationship between subgroups, PET parameters and progression free survival (PFS) was investigated.
Results : Of total 32 patients, 9 patients had a disease progression. Mean follow-up duration was 19.6 months (range, 1-60 mo). There were 24 patients with thymomas (5 with type A, 2 AB, 8 B1, 3 B2, 6 B3) and 8 with thymic carcinoma. Mean SUVmax (3.3±0.6 vs 5.9±3.2, p=0.005) and mean SULpeak (2.2±0.4 vs 4.0±1.7, p=0.001) of the low-risk group were significantly lower than that of the high-risk group. Optimal cut off value was 5.0 (Sensitivity: 88.9%, Specificity: 92%, AUC=0.95) in SUVmax and 3.3 (Sensitivity: 87.5%, Specificity: 97%, AUC=0.94) in SULpeak. Patients with lower SUVmax showed longer PFS (53.3±2.5 mo, 95% CI 48.3-58.2 mo) than those with higher SUVmax (10.0±1.2 mo, 95% CI 7.7-12.3 mo). Patients with lower SULpeak group showed longer PFS (52.9±2.9 mo, 95% CI 47.3-58.5 mo) than those with higher SULpeak (11.0±1.8 mo, 95% CI 7.6-28.9 mo). None in the low-risk group demonstrated progression during follow-up.
Conclusion : SUVmax and SULpeak from PET/CT were different between the low and high risk pathologic classification groups, and patients with higher FDG uptake showed shorter PFS. We suggest pretreatment quantification including SULpeak and SUVmax as useful prognostic tool in planning therapy of thymic epithelial tumors.
Methods : Between 2007 and 2014, the data of 32 patients (15 males, 17 females) diagnosed with thymic epithelial tumors who underwent PET/CT scan were retrospectively analyzed. Patients were divided into subgroups according to the histologic types: low-risk thymoma (type A, AB, B1) and high-risk thymoma (type B2, B3, C). We measured SULpeak and SUVmax to obtain the optimal cut-off values using ROC analysis. The high and low FDG uptake groups were divided according to the computed optimal cut-off values. The relationship between subgroups, PET parameters and progression free survival (PFS) was investigated.
Results : Of total 32 patients, 9 patients had a disease progression. Mean follow-up duration was 19.6 months (range, 1-60 mo). There were 24 patients with thymomas (5 with type A, 2 AB, 8 B1, 3 B2, 6 B3) and 8 with thymic carcinoma. Mean SUVmax (3.3±0.6 vs 5.9±3.2, p=0.005) and mean SULpeak (2.2±0.4 vs 4.0±1.7, p=0.001) of the low-risk group were significantly lower than that of the high-risk group. Optimal cut off value was 5.0 (Sensitivity: 88.9%, Specificity: 92%, AUC=0.95) in SUVmax and 3.3 (Sensitivity: 87.5%, Specificity: 97%, AUC=0.94) in SULpeak. Patients with lower SUVmax showed longer PFS (53.3±2.5 mo, 95% CI 48.3-58.2 mo) than those with higher SUVmax (10.0±1.2 mo, 95% CI 7.7-12.3 mo). Patients with lower SULpeak group showed longer PFS (52.9±2.9 mo, 95% CI 47.3-58.5 mo) than those with higher SULpeak (11.0±1.8 mo, 95% CI 7.6-28.9 mo). None in the low-risk group demonstrated progression during follow-up.
Conclusion : SUVmax and SULpeak from PET/CT were different between the low and high risk pathologic classification groups, and patients with higher FDG uptake showed shorter PFS. We suggest pretreatment quantification including SULpeak and SUVmax as useful prognostic tool in planning therapy of thymic epithelial tumors.
책임저자: 박재길
가톨릭대학교 의과대학 서울성모병원 흉부외과학교실
연락처 : 김경수, Tel: 02-2258-6320 , E-mail : cskks@catholic.ac.kr
